SpringWorks Therapeutics, Inc. Stock News

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announce

Start Time: 08:30 January 1, 0000 9:06 AM ET SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Saqib Islam - CEO Francis Per

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.18 per share a year ago.

– Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter –

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid t

STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announ

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno

STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced to

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in

– Reported OGSIVEO™ (nirogacestat) net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 –

STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc

STAMFORD, Conn., Jan. 31, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc

SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present

STAMFORD, Conn., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc